• 1
    Hsieh PH, Lee MS, Hsu KY, Chang YH, Shih HN, Ueng SW. Gram-negative prosthetic joint infections: risk factors and outcome of treatment. Clin Infect Dis 2009; 49: 10361043.
  • 2
    Martinez-Pastor JC, Munoz-Mahamud E, Vilchez F et al. Outcome of acute prosthetic joint infections due to gram-negative bacilli treated with open debridement and retention of the prosthesis. Antimicrob Agents Chemother 2009; 53: 47724777.
  • 3
    Brandt CM, Sistrunk WW, Duffy MC et al. Staphylococcus aureus prosthetic joint infection treated with debridement and prosthesis retention. Clin Infect Dis 1997; 24: 914919.
  • 4
    Brouqui P, Rousseau MC, Stein A, Drancourt M, Raoult D. Treatment of Pseudomonas aeruginosa-infected orthopedic prostheses with ceftazidime-ciprofloxacin antibiotic combination. Antimicrob Agents Chemother 1995; 39: 24232425.
  • 5
    Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004; 351: 16451654.
  • 6
    Di Bonaventura G, Spedicato I, D’Antonio D, Robuffo I, Piccolomini R. Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime. Antimicrob Agents Chemother 2004; 48: 151160.
  • 7
    Widmer AF, Wiestner A, Frei R, Zimmerli W. Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections. Antimicrob Agents Chemother 1991; 35: 741746.
  • 8
    Yassien M, Khardori N, Ahmedy A, Toama M. Modulation of biofilms of Pseudomonas aeruginosa by quinolones. Antimicrob Agents Chemother 1995; 39: 22622268.
  • 9
    Abdi-Ali A, Mohammadi-Mehr M, Agha Alaei Y. Bactericidal activity of various antibiotics against biofilm-producing Pseudomonas aeruginosa. Int J Antimicrob Agents 2006; 27: 196200.
  • 10
    Keays T, Ferris W, Vandemheen KL et al. A retrospective analysis of biofilm antibiotic susceptibility testing: a better predictor of clinical response in cystic fibrosis exacerbations. J Cyst Fibros 2009; 8: 122127.
  • 11
    Greenberg RN, Kennedy DJ, Reilly PM et al. Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin. Antimicrob Agents Chemother 1987; 31: 151155.
  • 12
    Zervos MJ, Hershberger E, Nicolau DP et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991–2000. Clin Infect Dis 2003; 37: 16431648.
  • 13
    Marculescu CE, Cantey JR. Polymicrobial prosthetic joint infections: risk factors and outcome. Clin Orthop Relat Res 2008; 466: 13971404.
  • 14
    Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998; 279: 15371541.
  • 15
    Marculescu CE, Berbari EF, Hanssen AD et al. Outcome of prosthetic joint infections treated with debridement and retention of components. Clin Infect Dis 2006; 42: 471478.